Surgical outcomes with neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in resectable NSCLC (AEGEAN)

Anthony Kim

Invited Discussant

Anthony W. Kim M.D., M.S. is the Chief of Division of Thoracic Surgery and Professor of Clinical Surgery in the Department of Surgery at the Keck School of Medicine and the Vice Chair, Clinical Operations for the Department of Surgery at the University of Southern California in Los Angeles, California. He is also the Co-Director of the Thoracic Oncology Program at the Keck and Norris Hospitals of the University of Southern California. 

David Harpole

Abstract Presenter

David H. Harpole, Jr. is a Professor of Surgery and Pathology at the Duke University in Durham, North Carolina, where he serves as Director of the Duke Surgical Research Fellowship and leads Duke’s Lung Cancer Research Laboratory and Biorepository.

Dr. Harpole has served in the Department of Surgery and Division of Thoracic Surgery for the past 20+ years; as Vice-chairman for Faculty Affairs, Vice-chief of The Division of Surgical Sciences and Vice Chairman for Research. He was the Co-chair of the Thoracic Tumor Committee of the National Cancer Database and recently retired as a Director of the American Board of Thoracic Surgery and completed his role as a Board of Director of the International Association for the Study of Lung Cancer. He was conference president of 2021 World Conference on Lung Cancer (WCLC).

Dr. Harpole has contributed numerous articles (> 200) and abstracts to the medical literature. His work on non-small cell lung cancer, esophageal carcinoma and mesothelioma. He has directed an active translational thoracic oncology research laboratory for more 25 years that has had National Institutes of Health, Veterans Affairs and Department of Defense peer reviewed grant support and has served on NCI and VA grant review study sections for more than 15 years, including chair of the NCI R03, R21, R33 grant review study section for the last 5 years. He has led several large multi-institutional lung cancer clinical trials based on his laboratory efforts. Over the last 8 years, he was the co-chair of the NCI-CTEP Thoracic Malignancies Steering Committee that oversees all large clinical trials in lung cancer and mesothelioma in the US and Canada.Over the last two+ decades, he has trained and mentored more than 20 research fellows who hold academic positions across the US and Canada. Currently, he is the PI of three NIH-funded training grants (NCI T32, NHLBI R38 and NIAID R38).